Retiring President

Katrina Campion
GlaxoSmithKline

My involvement in Clinical Research began more than 20 years ago. Prior to joining the Therapeutics Industry 15 years ago, I worked for 5 years as a Research Assistant/Study co-ordinator in epidemiology and preventive medicine at Monash University. Like many others I did not have a career plan in mind on leaving school. It was luck rather than good planning that allowed me to combine my undergraduate qualifications in Sociology and History (BA) and an accelerated registered nursing qualification! During this period I also completed a Graduate Diploma and Master of Arts Degree during this time and went on to also study in areas of computing and public health. In 1993 I joined Glaxo as a Clinical Research Associate. During my years at GSK, I have worked primarily as Clinical Research Manager across therapy areas and been responsible for trials through all phases. During 1998, I spent time working in our global head office in London as a Medical Communications Scientist and on my return to Australia in 1999 had the privilege of hosting the FDA whilst they audited a key registration trial which I had driven from inception to publication. Over the last few years I have also had the opportunity to be involved in activities in Japan and India which have enabled me to develop a hands on appreciation of the challenges of conducting global registration trials outside of ANZ.

Independent Director

Sian Slade
Bristol-Myers Squibb

Siân is an Independent Director with ARCS Australia and was appointed by the ARCS Board in October 2010. Siân was previously an elected Director on the ARCS board 2009/2010. Siân has 20 years experience in pharmacy and the pharmaceutical industry spanning a range of roles in clinical, medical, commercial and HR.

Originally based in Europe, Siân spent four years working in Australia establishing a consulting business and has recently moved to the US, initially working as a Client Services Director for a global medical communications company. Sian is now Group Director, Global Medical Information at Bristol-Myers Squibb based in Princeton, New Jersey. Siân is a pharmacist by background with an MBA from Imperial College, London. Sian is a Graduate of the Australian Institute of Directors.

Director

Ailsa Surman
Eli Lilly Australia

Ailsa holds degrees in biochemistry and pharmacology from the University of Auckland. She worked as an evaluator at Medsafe’s predecessor in the New Zealand Ministry of Health and for PHARMAC, before joining the pharmaceutical industry in New Zealand. She subsequently held global regulatory affairs and pharmacovigilance roles for 6 years in GSK’s UK headquarters. Since returning from the UK in 2005 Ailsa has been in the regulatory affairs team at Eli Lilly Australia, with responsibility for all aspects of regulatory support for a portfolio of products in both Australia and New Zealand. During this time Ailsa spent 18 months leading the regulatory team, managing personnel from the regulatory affairs, pharmacovigilance and product quality areas. Ailsa has been involved in the ARCS Regulatory Education Subcommittee since arriving in Australia, and has been co-convenor of the ESC for the past three years. During that time, working with a team of other enthusiastic volunteers, the ESC has delivered a wide range of educational events for regulatory professionals, including increasing numbers of opportunities for interaction with officials from the TGA and other regulatory bodies. Ailsa looks forward to bringing her understanding of the needs of ARCS’s regulatory members to the Board in order to work with other Directors to develop strategy that reflects the needs of all ARCS members.

Director

Judy Bingham
Easington Pty Ltd

Judy is currently an independent consultant to the biopharmaceutical industry, supporting companies plan and manage development and life cycle programs. Judy specialises in providing strategic and operational services to biopharmaceutical and health technology companies. Her aim is to add value to an organisation’s commercial objectives through an understanding of, and ability to integrate and manage the elements critical to the success of a program from lead identification through to marketing approval and post market commitments.

Director

Miriam Dwyer
Gallipoli Medical Research Foundation

Miriam is currently the Chief Executive Officer of the Gallipoli Medical Research Foundation, based at Greenslopes Private Hospital in Brisbane. This Foundation currently supports 3 academic research units (Liver Research Unit, lead by Prof Darrell Crawford, Centre for Immune & Targeted Therapy lead by Ass Prof Andrew Nicol and the Centre for NTM and Bronchiectasis Research, lead by Dr. Rachel Thompson). Working closely with the Chair of the Board of Directors, Miriam provides direction and leadership to the formulation and achievement of the GMRF’s goals and objectives. Miriam is responsible for the overall management and administration of the GMRF in the execution of the Directors’ policies. She leads the senior executive team and assume overall responsibility for the operation of the GMRF in consultation with the GMRF Executive. She oversees all operational elements of the Foundation’s Clinical Trials Unit, including feasibility assessments, contract negotiations, resource management and project delivery.

Director

Sarahann Simpson
Pfizer Australia

Sarahann Simpson is Country Safety Lead for Pfizer Australia. Sarahann has a Bachelor of Pharmacy degree from the University of Sydney and a Master of Science (Hons)(Ecotox.) from the University of Technology, Sydney. Sarahann joined the pharmaceutical industry originally in a medical Information role with Reckitt & Colman and from there she went on to work in regulatory affairs. In 1997, Sarahann began working in pharmacovigilance with 3M Pharmaceuticals before moving on to Merck Sharp and Dohme. Since 2004 Sarahann has worked in Drug Safety for Pfizer where her team handles spontaneous adverse event reports as well as serious adverse events from clinical trials and safety reporting to investigators. Sarahann has been a member of ARCS since 1984. She has been an active member of the ARCS Pharmacovigilance Education Subcommittee since its inception as well as serving for three years as Convenor. Sarahann is also a member of the Medicines Australia Pharmacovigilance Expert Advisory Group.

Director

Teresa Schafer
Piper Alderman

Dr Teresa Schafer is a partner in Piper Alderman's Corporate Group. She is both a lawyer and scientist, and has extensive experience in the regulation of therapeutic goods in Australia and New Zealand. She provides broad advice to clients in the pharmaceutical and medical device industry on regulatory and reimbursement issues; generic defence strategy; patent protection and infringement; clinical research issues; promotion and advertising; and product safety and recalls. In addition to her role at Piper Alderman, Teresa is a part-time member of the Administrative Appeals Tribunal, and hears matters in the General and Veterans Appeals Divisions, which includes reviewing decisions of the TGA.